A central role for neuronal adenosine 5′-monophosphate-activated protein kinase in cancer-induced anorexia

Endocrinology

Volumn 148, Issue 11, 2007, Pages 5220-5229

  Ropelle, Eduardo R ^a   Pauli, José R ^a   Zecchin, Karina G ^a   Ueno, Mirian ^a   De Souza, Cláudio T ^a   Morari, Joseane ^a   Faria, Marcel C ^a   Velloso, Lício A ^a   Saad, Mario J A ^a   Carvalheira, José B C ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE PHOSPHATE; DEOXYGLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; METFORMIN; NEUROPEPTIDE; PROOPIOMELANOCORTIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; FOOD INTAKE; HYPOTHALAMUS; INSULIN SENSITIVITY; MALE; NERVE CELL; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT;

AMINOIMIDAZOLE CARBOXAMIDE; ANIMALS; ANOREXIA; DEOXYGLUCOSE; DRUG ADMINISTRATION ROUTES; HYPOTHALAMUS; MALE; METFORMIN; MULTIENZYME COMPLEXES; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEURONS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, WISTAR; RIBONUCLEOTIDES; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 35548968099     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2007-0381     Document Type: Article

References (70)

1. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass Jr HO, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC 1980 Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69:491-497
2. Apolone G 2000 The state of research on multipurpose severity of illness scoring systems: are we on target? Intensive Care Med 26:1727-1729
3. Marks DL, Ling N, Cone RD 2001 Role of the central melanocortin system in cachexia. Cancer Res 61:1432-1438
4. Plata-Salaman CR 1991 Immunoregulators in the nervous system. Neurosci Biobehav Rev 15:185-215
5. Plata-Salaman CR 1997 Anorexia during acute and chronic disease: relevance of neurotransmitter-peptide-cytokine interactions. Nutrition 13:159-160
6. Wisse BE, Frayo RS, Schwartz MW, Cummings DE 2001 Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 142:3292-3301
7. Laviano A, Meguid MM, Rossi-Fanelli F 2003 Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol 4:686-694
8. Hosoi T, Okuma Y, Nomura Y 2002 The mechanisms of immune-to-brain communication in inflammation as a drug target. Curr Drug Targets Inflamm Allergy 1:257-262
9. Nonaka N, Hileman SM, Shioda S, Vo TQ, Banks WA 2004 Effects of lipopolysaccharide on leptin transport across the blood-brain barrier. Brain Res 1016:58-65
10. Inui A 1999 Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res 59:4493-4501
11. Chance WT, Balasubramaniam A, Dayal R, Brown J, Fischer JE 1994 Hypothalamic concentration and release of neuropeptide Y into microdialysates is reduced in anorectic tumor-bearing rats. Life Sci 54:1869-1874
12. Scarlett JM, Jobst EE, Enriori PJ, Bowe DD, Batra AK, Grant WF, Cowley MA, Marks DL 2007 Regulation of central melanocortin signaling by interleukin-1β. Endocrinology 148:4217-4225
13. Deboer MD, Marks DL 2006 Cachexia: lessons from melanocortin antagonism. Trends Endocrinol Metab 17:199-204
14. Gayle D, Ilyin SE, Romanovitch AE, Peloso E, Satinoff E, Plata-Salaman CR 1999 Basal and IL-1β-stimulated cytokine and neuropeptide mRNA expression in brain regions of young and old Long-Evans rats. Brain Res Mol Brain Res 70:92-100
15. Ramos EJ, Suzuki S, Meguid MM, Laviano A, Sato T, Chen C, Das U 2004 Changes in hypothalamic neuropeptide Y and monoaminergic system in tumor-bearing rats: pre- and post-tumor resection and at death. Surgery 136:270-276
16. Carvalheira JB, Siloto RM, Ignacchitti I, Brenelli SL, Carvalho CR, Leite A, Velloso LA, Gontijo JA, Saad MJ 2001 Insulin modulates leptin-induced STAT3 activation in rat hypothalamus. FEBS Lett 500:119-124
17. Schwartz MW, Porte Jr D 2005 Diabetes, obesity, and the brain. Science 307:375-379
18. Kim MS, Park JY, Namkoong C, Jang PG, Ryu JW, Song HS, Yun JY, Namgoong IS, Ha J, Park IS, Lee IK, Viollet B, Youn JH, Lee HK, Lee KU 2004 Anti-obesity effects of α-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat Med 10:727-733
19. Andersson U, Filipsson K, Abbott CR, Woods A, Smith K, Bloom SR, Carling D, Small CJ 2004 AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem 279:12005-12008
20. Lee K, Li B, Xi X, Suh Y, Martin RJ 2005 Role of neuronal energy status in the regulation of adenosine 5′-monophosphate-activated protein kinase, orexigenic neuropeptides expression, and feeding behavior. Endocrinology 146:3-10
21. Hardie DG, Salt IP, Hawley SA, Davies SP 1999 AMP-activated protein kinase: an ultrasensitive system for monitoring cellular energy charge. Biochem J 338(Pt 3):717-722
22. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, Cantley LC 2004 The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA101:3329-3335
23. Woods A, Dickerson K, Heath R, Hong SP, Momcilovic M, Johnstone SR, Carlson M, Carling D 2005 Ca2+/calmodulin-dependent protein kinase kinase-β acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2:21-33
24. Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM, Frenguelli BG, Hardie DG 2005 Calmodulin-dependent protein kinase kinase-β is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2:9-19
25. Hurley RL, Anderson KA, Franzone JM, Kemp BE, Means AR, Witters LA 2005 The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem 280:29060-29066
26. Giri S, Nath N, Smith B, Viollet B, Singh AK, Singh I 2004 5-Aminoimidazole-4-carboxamide-1-β-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J Neurosci 24:479-487
27. Ayasolla KR, Singh AK, Singh I 2005 5-Aminoimidazole-4- carboxamide-1-β-4-ribofuranoside (AICAR) attenuates the expression of LPS- and Abeta peptide-induced inflammatory mediators in astroglia. J Neuroinflammation 2:21
28. Jhun BS, Jin Q, Oh YT, Kim SS, Kong Y, Cho YH, Ha J, Baik HH, Kang I 2004 5-Aminoimidazole-4-carboxamide riboside suppresses lipopolysaccharide-induced TNF-α production through inhibition of phosphatidylinositol 3-kinase/Akt activation in RAW 264.7 murine macrophages. Biochem Biophys Res Commun 318:372-380
29. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, Mu J, Foufelle F, Ferre P, Birnbaum MJ, Stuck BJ, Kahn BB 2004 AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428:569-574
30. Bonora E, Moghetti P, Zancanaro C, Cigolini M, Querena M, Cacciatori V, Corgnati A, Muggeo M 1989 Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies. J Clin Endocrinol Metab 68:374-378
31. Scott AM, Atwater I, Rojas E 1981 A method for the simultaneous measurement of insulin release and B cell membrane potential in single mouse islets of Langerhans. Diabetologia 21:470-475
32. Schrier DJ, Ripani LM, Katzenstein AL, Moore VL 1982 Role of angiotensin-converting enzyme in Bacille Calmette-Guerin-induced granulomatous inflammation. Increased angiotensin-converting enzyme levels in lung lavage and suppression of inflammation with captopril. J Clin Invest 69:651-657
33. Gambardella A, Paolisso G, D'Amore A, Granato M, Verza M, Varricchio M 1993 Different contribution of substrates oxidation to insulin resistance in malnourished elderly patients with cancer. Cancer 72:3106-3113
34. Gomez-Ambrosi J, Zabalegui N, Bing C, Tisdale MJ, Trayhurn P, Williams G 2002 Weight loss in tumour-bearing mice is not associated with changes in resistin gene expression in white adipose tissue. Horm Metab Res 34:674-677
35. Ilyin SE, Gayle D, Gonzalez-Gomez I, Miele ME, Plata-Salaman CR 1999 Brain tumor development in rats is associated with changes in central nervous system cytokine and neuropeptide systems. Brain Res Bull 48:363-373
36. Opara EI, Laviano A, Meguid MM, Yang ZJ 1995 Correlation between food intake and CSF IL-1α in anorectic tumor bearing rats. Neuroreport 6:750-752
37. Laviano A, Gleason JR, Meguid MM, Yang ZJ, Cangiano C, Rossi Fanelli F 2000 Effects of intra-VMN mianserin and IL-1ra on meal number in anorectic tumor-bearing rats. J Invest Med 48:40-48
38. Matthys P, Billiau A 1997 Cytokines and cachexia. Nutrition 13:763-770
39. Plata-Salaman CR 2000 Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition 16:1009-1012
40. Bernardini R, Kamilaris TC, Calogero AE, Johnson EO, Gomez MT, Gold PW, Chrousos GP 1990 Interactions between tumor necrosis factor-α, hypothalamic corticotropin-releasing hormone, and adrenocorticotropin secretion in the rat. Endocrinology 126:2876-2881
41. Wisse BE, Schwartz MW, Cummings DE 2003 Melanocortin signaling and anorexia in chronic disease states. Ann NY Acad Sci 994:275-281
42. Bristulf J, Bartfai T 1995 Interleukin-1 β and tumour necrosis factor-alpha stimulate the mRNA expression of interleukin-1 receptors in mouse anterior pituitary AtT-20 cells. Neurosci Lett 187:53-56
43. Zhai QH, Futrell N, Chen FJ 1997 Gene expression of IL-10 in relationship to TNF-alpha, IL-1β and IL-2 in the rat brain following middle cerebral artery occlusion. J Neurol Sci 152:119-124
44. Rizk NM, Stammsen D, Preibisch G, Eckel J 2001 Leptin and tumor necrosis factor-α induce the tyrosine phosphorylation of signal transducer and activator of transcription proteins in the hypothalamus of normal rats in vivo. Endocrinology 142:3027-3032
45. King PJ, Widdowson PS, Doods H, Williams G 2000 Effect of cytokines on hypothalamic neuropeptide Y release in vitro. Peptides 21:143-146
46. Turnley AM, Stapleton D, Mann RJ, Witters LA, Kemp BE, Bartlett PF 1999 Cellular distribution and developmental expression of AMP-activated protein kinase isoforms in mouse central nervous system. J Neurochem 72:1707-1716
47. Sergeyev V, Broberger C, Gorbatyuk O, Hokfelt T 2000 Effect of 2-mercaptoacetate and 2-deoxy-D-glucose administration on the expression of NPY, AGRP, POMC, MCH and hypocretin/orexin in the rat hypothalamus. Neuroreport 11:117-121
48. Cheung W, Yu PX, Little BM, Cone RD, Marks DL, Mak RH 2005 Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 115:1659-1665
49. Markison S, Foster AC, Chen C, Brookhart GB, Hesse A, Hoare SR, Fleck BA, Brown BT, Marks DL 2005 The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. Endocrinology 146:2766-2773
50. Marks DL, Butler AA, Turner R, Brookhart G, Cone RD 2003 Differential role of melanocortin receptor subtypes in cachexia. Endocrinology 144:1513-1523
51. Gadalla AE, Pearson T, Currie AJ, Dale N, Hawley SA, Sheehan M, Hirst W, Michel AD, Randall A, Hardie DG, Frenguelli BG 2004 AICA riboside both activates AMP-activated protein kinase and competes with adenosine for the nucleoside transporter in the CA1 region of the rat hippocampus. J Neurochem 88:1272-1282
52. Corton JM, Gillespie JG, Hawley SA, Hardie DG 1995 5-Aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 229:558-565
53. Tzatsos A, Tsichlis PN 2007 Energy depletion inhibits phosphatidylinositol 3-kinase/Akt signaling and induces apoptosis via AMP-activated protein kinase-dependent phosphorylation of IRS-1 at Ser-794. J Biol Chem 282:18069-18082
54. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, Cantley LC 2004 The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6:91-99
55. Arpaci F, Yilmaz MI, Ozet A, Ayta H, Ozturk B, Komurcu S, Ozata M 2002 Low serum leptin level in colon cancer patients without significant weight loss. Tumori 88:147-149
56. Bolukbas FF, Kilic H, Bolukbas C, Gumus M, Horoz M, Turhal NS, Kavakli B 2004 Serum leptin concentration and advanced gastrointestinal cancers: a case controlled study. BMC Cancer 4:29
57. Dulger H, Alici S, Sekeroglu MR, Erkog R, Ozbek H, Noyan T, Yavuz M 2004 Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer. Int J Clin Pract 58:545-549
58. Simons JP, Schols AM, Campfield LA, Wouters EF, Saris WH 1997 Plasma concentration of total leptin and human lung-cancer-associated cachexia. Clin Sci (Lond) 93:273-277
59. Brown DR, Berkowitz DE, Breslow MJ 2001 Weight loss is not associated with hyperleptinemia in humans with pancreatic cancer. J Clin Endocrinol Metab 86:162-166
60. Wisse BE, Ogimoto K, Schwartz MW 2006 Role of hypothalamic interleukin-1β(IL-1β) in regulation of energy homeostasis by melanocortins. Peptides 27:265-273
61. Schwartz MW, Seeley RJ, Woods SC, Weigle DS, Campfield LA, Burn P, Baskin DG 1997 Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes 46:2119-2123
62. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC 2005 The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310:1642-1646
63. Khan AS, McLoughney CR, Ahmed AB 2006 The effect of metformin on blood glucose control in overweight patients with type 1 diabetes. Diabet Med 23:1079-1084
64. El-Batran SA, Abdel-Salam OM, Nofal SM, Baiuomy AR 2006 Effect of rosiglitazone and nateglinide on serum glucose and lipid profile alone or in combination with the biguanide metformin in diabetic rats. Pharmacol Res 53:69-74
65. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S 2001 Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 50:1457-1461
66. Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E, Streicher P, Sieve-Smith L, Tracy TM, Lang JE, McCullough P 2001 Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 50:856-861
67. Fruehwald-Schultes B, Oltmanns KM, Toschek B, Sopke S, Kern W, Born J, Fehm HL, Peters A 2002 Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men. Metabolism 51:531-536
68. Rouru J, Pesonen U, Koulu M, Huupponen R, Santti E, Virtanen K, Rouvari T, Jhanwar-Uniyal M 1995 Anorectic effect of metformin in obese Zucker rats: lack of evidence for the involvement of neuropeptide Y. Eur J Pharmacol 273:99-106
69. Kim YW, Kim JY, Park YH, Park SY, Won KC, Choi KH, Huh JY, Moon KH 2006 Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance. Diabetes 55:716-724
70. Chau-Van C, Gamba M, Salvi R, Gaillard RC, Pralong FP 2007 Metformin inhibits adenosine 5′-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons. Endocrinology 148:507-511